Overall, these studies indicate that IGF-1 treatment at presymptomatic stage protects the peripheral nerves from injury in B7-2−/− mice, and support the notion that IGF-1 therapy can be used in CIDP patients as a maintenance treatment to prevent relapses. This evidence concerns the gene IGF1 and chronic inflammatory demyelinating polyradiculoneuropathy.